Rikken Judith, Casteleijn Romee, van der Weide Marijke C, Duijnhoven Ruben, Goddijn Mariëtte, Mol Ben W, van der Veen Fulco, van Wely Madelon
Reproduction and Development Research Institute, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands
Department of Obstetrics and Gynaecology, Amsterdam UMC, Amsterdam, The Netherlands.
BMJ Open. 2025 Jan 21;15(1):e087766. doi: 10.1136/bmjopen-2024-087766.
We aim to assess which variables are associated with recruitment failure of obstetrical and gynaecological randomised controlled trials (RCTs), leading to an extension of the study period.
Nationwide study.
A cohort of RCTs supported by the trial centre of the Dutch Consortium of Obstetrics and Gynaecology.
We included 83 RCTs that recruited patients between 1 March 2003 and 1 December 2023.
Main outcome was recruitment target not achieved within 6 months after the preplanned recruitment period. Secondary outcomes were recruitment target not achieved within an extension period of at least 12 months and premature termination of the trial. In all RCTs, we collected information on variables with a potential effect on recruitment failure, recorded at five levels; patient, doctor, participating centre, study organisation and study design.
In total, 46 of 83 RCTs (55%) did not achieve their targeted recruitment within the preplanned study period with a maximal extension period of 6 months. The most relevant variables for recruitment failure in multivariable risk prediction modelling were presence of a no-treatment arm (where treatment is standard clinical practice), a compensation fee of less than €200 per included patient, funding of less than €350 000, while a preceding pilot study lowered this risk.
We identified that the presence of a no-treatment arm, low funding and a low compensation fee per included patient were the most relevant risk factors for recruitment failure within the preplanned period, while a preceding pilot study lowered this risk. Awareness of these variables is important when designing future studies.
我们旨在评估哪些变量与妇产科随机对照试验(RCT)的招募失败相关,这些失败会导致研究周期延长。
全国性研究。
由荷兰妇产科联盟试验中心支持的一组RCT。
我们纳入了83项在2003年3月1日至2023年12月1日期间招募患者的RCT。
主要结局是在预先计划的招募期后6个月内未达到招募目标。次要结局是在至少12个月的延长期内未达到招募目标以及试验提前终止。在所有RCT中,我们收集了可能对招募失败有影响的变量信息,记录在五个层面;患者、医生、参与中心、研究机构和研究设计。
83项RCT中共有46项(55%)在预先计划的研究期内未达到目标招募人数,最长延长期为6个月。多变量风险预测模型中与招募失败最相关的变量是存在无治疗组(治疗为标准临床实践)、每位纳入患者的补偿费用低于200欧元、资金低于35万欧元,而之前的预试验降低了这种风险。
我们发现存在无治疗组、资金不足和每位纳入患者的补偿费用低是预先计划期内招募失败的最相关风险因素,而之前的预试验降低了这种风险。在设计未来研究时,了解这些变量很重要。